Heartflow (HTFL) EBITDA Margin (2024 - 2025)
Heartflow's quarterly EBITDA Margin came in at 49.48% in Q4 2025, up 4413.0% year-on-year from 1.1% in Q4 2024, and up 54.8% quarter-over-quarter from 109.45% in Q3 2025.
Heartflow has reported EBITDA Margin for 2 years, with the latest figure at 49.48% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin rose 4413.0% year-over-year to 49.48%; the trailing twelve-month figure through Dec 2025 stood at 67.09% (changed N/A YoY), and the FY2025 full-year result was 66.15%, up 1071.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 49.48%, up from 109.45% in the prior quarter.
- The five-year high for EBITDA Margin was 20.51% in Q2 2025, with the low at 109.45% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn | 29.00% |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn | 3.36% |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn | 29.03% |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn | 19.09% |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn | 17.08% |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn | 27.87% |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn | -11.30% |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn | 1.25% |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn | 5.44% |
| 10 | Heartflow | 1.15 Bn | 974.90 Mn | 39.06 Mn | -49.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49.48% |
| Sep 30, 2025 | -109.45% |
| Jun 30, 2025 | -20.51% |
| Dec 31, 2024 | -93.61% |
| Sep 30, 2024 | -59.35% |
| Jun 30, 2024 | -75.61% |